Biogen and Ionis Pharmaceuticals announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations.    ALS with SOD1 mutations is a subtype of familial ALS and accounts for approximately two percent of all ALS cases. “Biogen and Ionis have a shared goal of bringing inn...